Deletion of rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex

Human Molecular Genetics

Volumn 22, Issue 1, 2013, Pages 140-152

  Carson, Robert P ^a   Fu, Cary ^a   Winzenburger, Peggy ^a   Ess, Kevin C ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MONOAMINE; NEUROTRANSMITTER; PROTEIN; RICTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN FUNCTION; CONTROLLED STUDY; ELECTROENCEPHALOGRAPHY; FEMALE; FERTILITY; GENE DELETION; HYPERACTIVITY; LIFESPAN; MALE; MONOAMINERGIC SYSTEM; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; WHITE MATTER;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CARRIER PROTEINS; ELECTROENCEPHALOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE; GENE DELETION; MICE; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; SEIZURES; SIGNAL TRANSDUCTION; SLEEP; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS;

MAMMALIA; MUS;

EID: 84871194183     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds414     Document Type: Article

References (83)

1. Kim, D.H., Sarbassov, D.D., Ali, S.M., King, J.E., Latek, R.R., Erdjument-Bromage, H., Tempst, P. and Sabatini, D.M. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell, 110, 163-175.
2. Liu, L.H., Das, S., Losert, W. and Parent, C.A. (2010) mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. Dev. Cell, 19, 845-857.
3. Fingar, D.C., Richardson, C.J., Tee, A.R., Cheatham, L., Tsou, C. and Blenis, J. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell Biol., 24, 200-216.
4. Hay, N. and Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes Dev., 18, 1926-1945.
5. Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., Markhard, A.L. and Sabatini, D.M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell., 22, 159-168.
6. Inoki, K., Li, Y., Xu, T. and Guan, K.L. (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev., 17, 1829-1834.
7. Huang, J.X., Dibble, C.C., Matsuzaki, M. and Manning, B.D. (2008) The TSC1-TSC2 complex is required for proper activation of mTOR complex Mol. Cell. Biol., 28, 4104-4115.
8. Huang, J., Wu, S., Wu, C.L. and Manning, B.D. (2009) Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res., 69, 6107-6114.
9. Carson, R.P., Van Nielen, D.L., Winzenburger, P.A. and Ess, K.C. (2012) Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. Neurobiol. Dis., 45, 369-380.
10. Jacinto, E. and Lorberg, A. (2008) TOR regulation of AGC kinases in yeast and mammals. Biochem. J., 410, 19-37.
11. Cameron, A.J., Linch, M.D., Saurin, A.T., Escribano, C. and Parker, P.J. (2011) mTORC2 targets AGC kinases through Sin1-dependent recruitment. Biochem. J., 439, 287-297.
12. Bellacosa, A., Chan, T.O., Ahmed, N.N., Datta, K., Malstrom, S., Stokoe, D., McCormick, F., Feng, J. and Tsichlis, P. (1998) Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene, 17, 313-325.
13. Liao, Y. and Hung, M.C. (2010) Physiological regulation of Akt activity and stability. Am. J. Transl. Res., 2, 19-42.
14. Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., Moffat, J., Brown, M., Fitzgerald, K.J. and Sabatini, D.M. (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell, 11, 859-871.
15. Shiota, C., Woo, J.T., Lindner, J., Shelton, K.D. and Magnuson, M.A. (2006) Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell, 11, 583-589.
16. Siuta, M.A., Robertson, S.D., Kocalis, H., Saunders, C., Gresch, P.J., Khatri, V., Shiota, C., Kennedy, J.P., Lindsley, C.W., Daws, L.C. et al. (2010) Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice. PLoS Biol., 8, e1000393. doi:1000310.1001371/ journal.pbio.1000393
17. Gorski, J.A., Talley, T., Qiu, M., Puelles, L., Rubenstein, J.L. and Jones, K.R. (2002) Cortical excitatory neurons and glia, but not GABAergic neurons, are produced in the Emx1-expressing lineage. J. Neurosci., 22, 6309-6314.
18. Kessaris, N., Fogarty, M., Iannarelli, P., Grist, M., Wegner, M. and Richardson, W.D. (2006) Competing waves of oligodendrocytes in the forebrain and postnatal elimination of an embryonic lineage. Nat. Neurosci., 9, 173-179.
19. Zhou, X., Ikenoue, T., Chen, X., Li, L., Inoki, K. and Guan, K.-L. (2009) Rheb controls misfolded protein metabolism by inhibiting aggresome formation and autophagy. Proc. Natl. Acad. Sci. USA, 106, 8923-8928.
20. Lee, P.S., Tsang, S.W., Moses, M.A., Trayes-Gibson, Z., Hsiao, L.L., Jensen, R., Squillace, R. and Kwiatkowski, D.J. (2010) Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am. J. Respir. Cell Mol. Biol., 42, 227-234.
21. Neuman, N.A. and Henske, E.P. (2011) Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis. EMBO Mol. Med., 3, 189-200.
22. Way, S.W., Rozas, N.S., Wu, H.C., McKenna, J, 3rd, Reith, R.M., Hashmi, S.S., Dash, P.K. and Gambello, M.J. (2012) The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex. Hum. Mol. Genet., 21, 3226-3236.
23. Thiele, E.A. (2004) Managing epilepsy in tuberous sclerosis complex. J. Child Neurol., 19, 680-686.
24. Holmes, G.L. and Stafstrom, C.E. (2007) Tuberous sclerosis complex and epilepsy: recent developments and future challenges. Epilepsia, 48, 617-630.
25. Uhlmann, E.J., Wong, M., Baldwin, R.L., Bajenaru, M.L., Onda, H., Kwiatkowski, D.J., Yamada, K. and Gutmann, D.H. (2002) Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol., 52, 285-296.
26. Zeng, L.H., Rensing, N.R., Zhang, B., Gutmann, D.H., Gambello, M.J. and Wong, M. (2011) Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum. Mol. Genet., 20, 445-454.
27. Fu, C., Cawthon, B., Clinkscales, W., Bruce, A., Winzenburger, P. and Ess, K.C. (2011) GABAergic interneuron development and function is modulated by the Tsc1 gene. Cerebral Cortex, 22, 2111-2119.
28. Morley, B.J. and Bradley, R.J. (1977) Spectral analysis of mouse EEG after the administration of N, N-dimethyltryptamine. Biol. Psychiatry, 12, 757-769.
29. Handforth, A., Delorey, T.M., Homanics, G.E. and Olsen, R.W. (2005) Pharmacologic evidence for abnormal thalamocortical functioning in GABA receptor beta3 subunit-deficient mice, a model of Angelman syndrome. Epilepsia, 46, 1860-1870.
30. Arulrajah, S., Ertan, G., Jordan, L., Tekes, A., Khaykin, E., Izbudak, I. and Huisman, T. (2009) Magnetic resonance imaging and diffusion-weighted imaging of normal-appearing white matter in children and young adults with tuberous sclerosis complex. Neuroradiology, 51, 781-786.
31. Widjaja, E., Simao, G., Mahmoodabadi, S.Z., Ochi, A., Snead, O.C., Rutka, J. and Otsubo, H. (2010) Diffusion tensor imaging identifies changes in normal-appearing white matter within the epileptogenic zone in tuberous sclerosis complex. Epilepsy Res., 89, 246-253.
32. Simao, G., Raybaud, C., Chuang, S., Go, C., Snead, O.C. and Widjaja, E. (2010) Diffusion tensor imaging of commissural and projection white matter in tuberous sclerosis complex and correlation with tuber load. Am. J. Neuroradiol., 31, 1273-1277.
33. Meikle, L., Talos, D.M., Onda, H., Pollizzi, K., Rotenberg, A., Sahin, M., Jensen, F.E. and Kwiatkowski, D.J. (2007) A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci., 27, 5546-5558.
34. Van Veen, M.M., Kooij, J.J., Boonstra, A.M., Gordijn, M.C. and Van Someren, E.J. (2010) Delayed circadian rhythm in adults with attention-deficit/hyperactivity disorder and chronic sleep-onset insomnia. Biol. Psychiatry, 67, 1091-1096.
35. Weiss, M.D. and Salpekar, J. (2010) Sleep problems in the child with attention-deficit hyperactivity disorder: defining aetiology and appropriate treatments. CNS Drugs, 24, 811-828.
36. Yoon, S.Y., Jain, U. and Shapiro, C. (2011) Sleep in attention-deficit/ hyperactivity disorder in children and adults: past, present, and future. Sleep Med. Rev., 16, 371-388.
37. Hunt, A. and Stores, G. (1994) Sleep disorder and epilepsy in children with tuberous sclerosis: a questionnaire-based study. Dev. Med. Child Neurol., 36, 108-115.
38. Bruni, O., Cortesi, F., Giannotti, F. and Curatolo, P. (1995) Sleep disorders in tuberous sclerosis: a polysomnographic study. Brain Dev., 17, 52-56.
39. van Eeghen, A.M., Numis, A.I., Staley, B.A., Therrien, S.E., Thibert, R.L. and Thiele, E.A. (2011) Characterizing sleep disorders of adults with tuberous sclerosis complex: a questionnaire-based study and review. Epilepsy Behav., 20, 68-74.
40. Lewis, J.C., Thomas, H.V., Murphy, K.C. and Sampson, J.R. (2004) Genotype and psychological phenotype in tuberous sclerosis. J. Med. Genet., 41, 203-207.
41. Muzykewicz, D.A., Newberry, P., Danforth, N., Halpern, E.F. and Thiele, E.A. (2007) Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav., 11, 506-513.
42. Kash, S.F., Tecott, L.H., Hodge, C. and Baekkeskov, S. (1999) Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc. Natl. Acad. Sci. USA, 96, 1698-1703.
43. Tang, X. and Sanford, L.D. (2005) Home cage activity and activity-based measures of anxiety in 129P3/J, 129X1/SvJ and C57BL/6J mice. Physiol. Behav., 84, 105-115.
44. Acevedo, S.F., Ohtsu, H., Benice, T.S., Rizk-Jackson, A. and Raber, J. (2006) Age-dependent measures of anxiety and cognition in male histidine decarboxylase knockout (Hdc-/-) mice. Brain Res., 1071, 113-123.
45. Uchiumi, K., Aoki, M., Kikusui, T., Takeuchi, Y. and Mori, Y. (2008) Wheel-running activity increases with social stress in male DBA mice. Physiol. Behav., 93, 1-7.
46. Weber, M., Talmon, S., Schulze, I., Boeddinghaus, C., Gross, G., Schoemaker, H. and Wicke, K.M. (2009) Running wheel activity is sensitive to acute treatment with selective inhibitors for either serotonin or norepinephrine reuptake. Psychopharmacology (Berl), 203, 753-762.
47. Deacon, R.M. (2006) Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat. Protoc., 1, 122-124.
48. Witkin, J.M. (2008) Animal models of obsessive-compulsive disorder. Curr. Protoc. Neurosci.
49. Giros, B., Jaber, M., Jones, S.R., Wightman, R.M. and Caron, M.G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 379, 606-612.
50. Kakefuda, K., Oyagi, A., Ishisaka, M., Tsuruma, K., Shimazawa, M., Yokota, K., Shirai, Y., Horie, K., Saito, N., Takeda, J. et al. (2010) Diacylglycerol kinase beta knockout mice exhibit lithium-sensitive behavioral abnormalities. PLoS One, 5, e13447.
51. Li, Y.C. and Gao, W.J. (2011) GSK-3beta activity and hyperdopamine-dependent behaviors. Neurosci. Biobehav. Rev., 35, 645-654.
52. Um, S.H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P.R., Kozma, S.C., Auwerx, J. et al. (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature, 431, 200-205.
53. Gan, X.Q., Wang, J.Y., Su, B. and Wu, D.Q. (2011) Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem., 286, 10998-11002.
54. Tschopp, O., Yang, Z.Z., Brodbeck, D., Dummler, B.A., Hemmings-Mieszczak, M., Watanabe, T., Michaelis, T., Frahm, J. and Hemmings, B.A. (2005) Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development, 132, 2943-2954.
55. Narayanan, S.P., Flores, A.I., Wang, F. and Macklin, W.B. (2009) Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J. Neurosci., 29, 6860-6870.
56. Barros, C.S., Nguyen, T., Spencer, K.S., Nishiyama, A., Colognato, H. and Muller, U. (2009) Beta1 integrins are required for normal CNS myelination and promote AKT-dependent myelin outgrowth. Development, 136, 2717-2724.
57. Tyler, W.A., Gangoli, N., Gokina, P., Kim, H.A., Covey, M., Levison, S.W. and Wood, T.L. (2009) Activation of the mammalian target of rapamycin (mtor) is essential for oligodendrocyte differentiation. J. Neurosci., 29, 6367-6378.
58. Dummler, B., Tschopp, O., Hynx, D., Yang, Z.Z., Dirnhofer, S. and Hemmings, B.A. (2006) Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol. Cell Biol., 26, 8042-8051.
59. Franz, D.N., Care, M.M., Holland-Bouley, K., Agricola, K., Tudor, C., Mangeshkar, P., Weber-Byars, A., Sahmoud, T., Tillema, J. and Krueger, D.A. (2011) Everolimus reduced seizure activity and altered the microarchitecture of CNS white matter in patients with tuberous sclerosis complex. Ann. Neurol., 70, S118.
60. Tillema, J.M., Leach, J.L., Krueger, D.A. and Franz, D.N. (2012) Everolimus alters white matter diffusion in tuberous sclerosis complex. Neurology, 78, 526-531.
61. Thatcher, R.W., Biver, C., McAlaster, R., Camacho, M. and Salazar, A. (1998) Biophysical linkage between MRI and EEG amplitude in closed head injury. Neuroimage, 7, 352-367.
62. Gloor, P., Ball, G. and Schaul, N. (1977) Brain lesions that produce delta waves in EEG. Neurology, 27, 326-333.
63. Gloor, P., Kalabay, O. and Giard, N. (1968) Electroencephalogram in diffuse encephalopathies-electroencephalographic correlates of grey and white matter lesions. Brain, 91, 779-790.
64. Magnuson, M.A., Shiota, C., Woo, J.T., Lindner, J. and Shelton, K.D. (2006) Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell, 11, 583-589.
65. Hresko, R.C. and Mueckler, M. (2005) mTOR center dot RICTOR is the Ser(473) kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem., 280, 40406-40416.
66. Cybulski, N., Polak, P., Auwerx, J., Ruegg, M.A. and Hall, M.N. (2009) mTOR complex 2 in adipose tissue negatively controls whole-body growth. P. Natl. Acad. Sci. USA, 106, 9902-9907.
67. Sarbassov, D.D., Guertin, D.A., Ali, S.M. and Sabatini, D.M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
68. Biondi, R.M., Kieloch, A., Currie, R.A., Deak, M. and Alessi, D.R. (2001) The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J., 20, 4380-4390.
69. Scheid, M.P., Marignani, P.A. and Woodgett, J.R. (2002) Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol. Cell. Biol., 22, 6247-6260.
70. Bentzinger, C.F., Romanino, K., Cloetta, D., Lin, S., Mascarenhas, J.B., Oliveri, F., Xia, J.Y., Casanova, E., Costa, C.F., Brink, M. et al. (2008) Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab., 8, 411-424.
71. Beaulieu, J.M., Sotnikova, T.D., Marion, S., Lefkowitz, R.J., Gainetdinov, R.R. and Caron, M.G. (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell, 122, 261-273.
72. Ackermann, T.F., Kempe, D.S., Lang, F. and Lang, U.E. (2010) Hyperactivity and enhanced curiosity of mice expressing PKB/ SGK-resistant glycogen synthase kinase-3 (GSK-3). Cell Physiol. Biochem., 25, 775-786.
73. Trantham-Davidson, H., Vazdarjanova, A., Dai, R., Terry, A. and Bergson, C. (2008) Up-regulation of calcyon results in locomotor hyperactivity and reduced anxiety in mice. Behav. Brain Res., 189, 244-249.
74. Beaulieu, J.M., Gainetdinov, R.R. and Caron, M.G. (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Ann. Rev. Pharm. Tox., 49, 327-347.
75. Beaulieu, J.M. (2011) A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J. Psych. & Neurosci., 36, 110011.
76. Parent, A. and Hazrati, L.N. (1995) Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Rev., 20, 91-127.
77. Singer, H.S., Morris, C. and Grados, M. (2010) Glutamatergic modulatory therapy for Tourette syndrome. Med. Hypotheses, 74, 862-867.
78. Shiflett, M.W. and Balleine, B.W. (2011) Molecular substrates of action control in cortico-striatal circuits. Prog. Neurobiol., 95, 1-13.
79. Cocas, L.A., Miyoshi, G., Carney, R.S., Sousa, V.H., Hirata, T., Jones, K.R., Fishell, G., Huntsman, M.M. and Corbin, J.G. (2009) Emx1-lineage progenitors differentially contribute to neural diversity in the striatum and amygdala. J. Neurosci., 29, 15933-15946.
80. Ess, K.C., Kamp, C.A., Tu, B.P. and Gutmann, D.H. (2005) Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. Neurology, 64, 1446-1449.
81. Perez, F.A. and Palmiter, R.D. (2005) Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. USA, 102, 2174-2179.
82. Cook, M.N., Williams, R.W. and Flaherty, L. (2001) Anxiety-related behaviors in the elevated zero-maze are affected by genetic factors and retinal degeneration. Behav. Neurosci., 115, 468-476.
83. Kulkarni, S.K., Singh, K. and Bishnoi, M. (2007) Elevated zero maze: a paradigm to evaluate antianxiety effects of drugs. Methods Find. Exp. Clin. Pharmacol., 29, 343-348.